alexa Management Of Cardiovascular Disease In Hemophilia
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Jean-Francois Schved
Montpellier University Hospital, France
ScientificTracks Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-022
Abstract
With the well-known increase of the life expectancy in patients with hemophilia (PWH), patients are faced with age-related comorbidities. Thus, over the last few years, hematologists appear to be witnessing an increase in the frequency of cardiovascular diseases, mainly ischemic cardiopathies or atrial fibrillation. These diseases raise major difficulties in PWH while the recommended treatments rely on antiplatelet agents and anticoagulants. Anticoagulants and antiplatelet treatments increase the risk of bleeding in hemophiliacs and cardiovascular interventions commonly complicate bleeding. To minimize these risks, the clotting factor deficiency needs to be adapted. To get more information on the possibility of treatment, we launched an observational study called COCHE (comorbidity of cardiovascular origin in hemophilia) including PWH treated for atrial fibrillation or ischemic cardiopathies. Some patients underwent endovascular procedures, the minimal follow-up being two years. From these data, it appears that anti-platelet agents can be used with caution and under certain conditions in most hemophiliacs. Invasive cardiovascular interventions are possible and anticoagulants treatments or dual anti-platelet therapy can often be used. In all cases, close collaboration between the cardiologist and hematologist is necessary to offer the patient an optimum treatment.
Biography

Jean-François Schved is a Doctor and Professor of Hematology at Faculty of Medicine, Montpellier University. His main theme of study and research is Haemostasis, especially hemorrhagic disease and hemophilia. His other research work focused on Thrombotic disease and the risk factors for thrombosis. His team has also conducted important scientific work on red blood cells and genetic iron overload. He published, in collaboration with various units of research or hospital services, more than 200 scientific articles in international journals and participated in writing of many medical books. He frequently reviews manuscripts for major journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords